Valneva's 15-min chart triggers Bollinger Bands narrowing, KDJ death cross, bearish Marubozu.

Based on Valneva's 15-minute chart, several technical indicators have triggered. The narrowing of Bollinger Bands suggests that the magnitude of stock price fluctuations is decreasing. The KDJ Death Cross and bearish Marubozu at 08/28/2025 14:00 indicate a shift in momentum towards the downside, which may lead to further decreases in stock price. Sellers currently control the market, and there is a likelihood of continued bearish momentum.

Valneva SE (VALN) faced a significant setback on Monday, August 25, 2025, as the United States Food and Drug Administration (FDA) suspended the license for its chikungunya vaccine, Ixchiq. The suspension, effective immediately, is based on four new reports of serious adverse events consistent with chikungunya-like illness. All four cases occurred outside the U.S., with three involving individuals aged 70 to 82 years and one a 55-year-old individual. An 82-year-old was hospitalized and discharged after two days [1].

The suspension requires Valneva to cease shipping and selling Ixchiq in the United States. The company has stated that it believes the cases describe symptoms consistent with those reported during clinical trials but is continuing to investigate the incidents in detail. Valneva is evaluating the financial impact of the withdrawal of Ixchiq’s license in the U.S. but has not modified its revenue guidance. In the first half of 2025, Ixchiq contributed €7.5 million ($8.74 million) to the company’s €91 million total product sales [1].

Following the FDA's decision, Valneva shares tumbled over 19% on Monday, with the stock down to $9.13 from $11.26 at the beginning of the day. Analysts expressed divergent opinions on the vaccine company. Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 while keeping a ‘Buy’ rating on the shares. H.C. Wainwright analyst Brandon Folkes, meanwhile, reiterated a ‘Buy’ rating on Valneva, noting that the stock selloff on Monday offers an attractive entry for investors who are constructive on a potential positive readout for VLA15, the company’s investigational Lyme disease vaccine, later this year [2].

On Stocktwits, retail sentiment around Valneva remained within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. A Stocktwits user remains hopeful about the company getting acquired, while another said they are cutting their risk [1].

Valneva has shown remarkable strength year-to-date, with a 166% gain. However, the stock is currently in overbought territory, and technical indicators suggest a shift in momentum towards the downside. The narrowing of Bollinger Bands and the KDJ Death Cross and bearish Marubozu at 08/28/2025 14:00 indicate a potential further decrease in stock price [3].

References:
[1] https://stocktwits.com/news-articles/markets/equity/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe
[2] https://www.ainvest.com/news/valneva-chikungunya-vaccine-sales-suspended-2508/
[3] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311